Daniel Jachimowicz
Overview
Explore the profile of Daniel Jachimowicz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
526
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pham V, Rodel C, Valentino M, Malinverno M, Paolini A, Munch J, et al.
EMBO Mol Med
. 2024 Oct;
16(11):2827-2855.
PMID: 39402138
Cerebral cavernous malformations (CCMs) are anomalies of the cerebral vasculature. Loss of the CCM proteins CCM1/KRIT1, CCM2, or CCM3/PDCD10 trigger a MAPK-Krüppel-like factor 2 (KLF2) signaling cascade, which induces a...
2.
Asowata E, Romoli S, Sargeant R, Tan J, Hoffmann S, Huang M, et al.
Kidney Int
. 2024 Mar;
106(1):85-97.
PMID: 38431215
Despite the recent advances in our understanding of the role of lipids, metabolites, and related enzymes in mediating kidney injury, there is limited integrated multi-omics data identifying potential metabolic pathways...
3.
Vaid R, Thombare K, Mendez A, Burgos-Panadero R, Djos A, Jachimowicz D, et al.
Nucleic Acids Res
. 2024 Jan;
52(5):2648-2671.
PMID: 38180812
Telomerase-negative tumors maintain telomere length by alternative lengthening of telomeres (ALT), but the underlying mechanism behind ALT remains poorly understood. A proportion of aggressive neuroblastoma (NB), particularly relapsed tumors, are...
4.
Ali M, Di Marco M, Mahale S, Jachimowicz D, Thankaswamy Kosalai S, Reischl S, et al.
Oncogene
. 2021 Mar;
40(13):2463-2478.
PMID: 33674747
Recent advances in genomics unraveled several actionable mutational drivers in lung cancer, leading to promising therapies such as tyrosine kinase inhibitors and immune checkpoint inhibitors. However, the tumors' acquired resistance...
5.
Mitra S, Muralidharan S, Di Marco M, Juvvuna P, Thankaswamy Kosalai S, Reischl S, et al.
Cancer Res
. 2020 Dec;
81(6):1457-1471.
PMID: 33372039
Neuroblastoma has a low mutation rate for the gene. Alternative ways of p53 inactivation have been proposed in neuroblastoma, such as abnormal cytoplasmic accumulation of wild-type p53. However, mechanisms leading...
6.
Garalde D, Snell E, Jachimowicz D, Sipos B, Lloyd J, Bruce M, et al.
Nat Methods
. 2018 Jan;
15(3):201-206.
PMID: 29334379
Sequencing the RNA in a biological sample can unlock a wealth of information, including the identity of bacteria and viruses, the nuances of alternative splicing or the transcriptional state of...
7.
Luczak A, Supernat A, Lapinska-Szumczyk S, Jachimowicz D, Majewska H, Gulczynski J, et al.
Int J Biol Markers
. 2016 Feb;
31(3):e245-51.
PMID: 26868332
Background: Endometrial cancer (EC) is a hormone-related disease, showing highly diverse features of ER/PR/HER2 status-based molecular subtypes. Long noncoding RNA (lncRNA) HOX antisense intergenic RNA (HOTAIR) has recently emerged as...